AMCP Strategic Priorities — Quarterly Update Aug. 2021
In the spring of 2021, AMCP introduced three strategic priorities that frame the immediate work that will help to get more patients the medications they need at a cost they can afford. This is the first quarterly update showcasing AMCP’s accomplishments.
Work Completed from Apr. 2021 through Aug. 2021:
Encourage the exchange of ideas that optimize patient’s health outcome and address barriers to care. Areas of focus include value, access and affordability, technologies, and quality.
Promote Adoption and Access to Biosimilars
In June, AMCP conducted a webinar — Biosimilars: Policy, Practice, and Post Marketing Surveillance to Support Treatment and Coverage Decisions — to explore high-level findings from an AMCP Partnership Forum that identified actions to support further development and use of biosimilars in the U.S. health care system. Full proceedings from the Dec. 2020 Partnership Forum will be published in the Journal of Managed Care + Specialty Pharmacy in the coming months. Additional efforts to disseminate education and best practices to advance the adoption of biosimilars included AMCP Talks: Success Stories in Biosimilar Adoption during our spring eLearning Days.
On July 29, AMCP released a statement applauding the FDA’s approval of the first interchangeable biosimilar insulin product. This approval allows pharmacists to substitute biosimilar insulin for the innovator insulin at the pharmacy counter for the first time. This action means that more people will be able to access insulin products, resulting in better care at a lower cost. Read AMCP’s Statement
Explore more of AMCP’s biosimilar resources and visit the Biologic and Biosimilars Collective Intelligence Consortium (BBCIC) to learn more about research initiatives.
In August, AMCP hosted a Partnership Forum called Digital Therapeutics 2.0 to explore the emerging and important area of therapeutics. This event continued to explore themes discussed in our Sept. 2019 forum, Digital Therapeutics: What Are They and Where Do They Fit in Pharmacy and Medical Benefits?, in which we developed a definition of digital therapeutics, taking particular note of how they contrast from other digital health as consumer wellness apps, and considered whether digital therapeutics are better suited for the pharmacy or medical benefit. Digital Therapeutics 2.0 defined principles for coverage decisions.
AMCP staff and members also continue to engage with the Digital Therapeutics Association (DTA) by serving on the payer advisory panel and providing feedback on a draft guidance, Digital Therapeutics Value Assessment and Integration Guide developed by DTA.
Advance Key Quality Issues
AMCP’s efforts on quality are intended to span an array of activities including quality measure development, accreditation, and patient outcomes. In June 2021, AMCP submitted comments to CMS in response to its Information Collection Request titled Medication Therapy Management Improvements – Standardized Format. In that letter, AMCP supported proposed changes that aligned with the results from a beneficiary survey published in 2019, provided additional suggestions for improvement, and urged the agency to delay implementation of the new format until Jan. 2023 to allow Part D plans adequate time to develop and test needed changes. On July 28, AMCP signed onto a Medicare Part D stakeholder letter urging HHS to extend the Enhanced Medication Therapy Management (EMTM) Model which is currently set to expire on Dec. 31, 2021.
As a founding member of the Pharmacy Quality Alliance (PQA), AMCP was pleased to provide comments on their strategic priorities. That input emphasized the need to consider a medication’s cost-effectiveness when developing medication use quality measures. AMCP also encouraged PQA to define objective criteria and processes for when a measure or measures would be retired due to attainment of a measure’s intended goal. AMCP supported PQA’s goal to address health disparities in medication use quality, which aligns with AMCP’s strategic priority around addressing health disparities in medication access, use, and outcomes.
In the coming months, AMCP plans to establish an advisory group to inform its work on the important topic of quality. Details on how to get involved will be coming soon!
Serve as a needed voice and convener around the role that managed care pharmacy can play in identifying and reducing health disparities.
In Mar. 2021, AMCP held the Partnership Forum, Racial Health Disparities: A Closer Look at Benefit Design. The event brought together diverse stakeholders to identify viable solutions to reduce racial health disparities in the use of drugs and related therapies. Following the forum, AMCP published the executive summary of outcomes, scheduled a webinar to explore the outcomes on Sept. 16, and will publish the proceedings in the Journal of Managed Care + Specialty Pharmacy in early fall.
AMCP is also focused on providing educational content and resources on this topic including recordings from our national meetings on medication adherence, the effect of racism on health, and social determinants of health. AMCP Nexus 2021 will feature an AMCP Talks session on health disparities. In the coming months, AMCP will also issue a call for members to submit their best practices for addressing health disparities. Get your stories ready!
An updated AMCP and AMCP Foundation research agenda includes a new research priority to identify how health care disparities are impacted and reduced through managed care tools and interventions, while maximizing adherence and addressing affordability within disparate populations. The origin of this priority is described in this poster presented at AMCP 2021. A session at Nexus 2021 will discuss this research priority in more detail as well.
In July, AMCP submitted comments to the Office of Management and Budget in response to a request for information on how the government can advance equity in underserved communities. AMCP emphasized the importance of continuous Medicaid enrollment to avoid disruptions in care and the need to simplify Medicare Part D low-income subsidy enrollment.
Ensure that managed care pharmacy is a leader in efforts to optimize value and access and address health disparities by growing membership and highlighting the expertise of members and corporate partners.
AMCP recognizes that the organization’s strength lies in the rich landscape of its membership, staff, and leadership. A new Diversity, Equity, and Inclusion statement developed by the membership committee reflects the commitment to expand and increase understanding of our diversity to fully realize our mission:
AMCP’s Commitment to Diversity, Equity, and Inclusion
To fulfill the mission of getting patients the medications and therapies they need at a cost they can afford, it is imperative that AMCP’s membership, staff, and leadership reflect the rich landscape of our populations. By respecting and including everyone who drives the daily victories in managed care pharmacy, we will benefit from a mix of ideas, perspectives, and life experiences to help us achieve our goals.
AMCP recently launched a new web page to underscore the value of AMCP membership for managed care practitioners, including opportunities for networking, education, leadership skill development, and much more. A second web page highlights exclusive AMCP member benefits, including continuing education, health care decision-making tools, networking, volunteer leadership opportunities, newsletters, and more. A third page explores the benefits of corporate membership including education and awareness, market research, meetings, and networking and collaborating in AMCP’s thought leadership activities.
August also marked the one-year anniversary of AMCP Collaborate — a platform for AMCP members to connect and share ideas and solutions about the most vexing challenges in health care today. Successes to date include 70 communities, over 1,100 connections made, and more than 3,300 content postings. Join the discussion today!